DCR Cancer Research Results

DCR, Disease control rate: Click to Expand ⟱
Source:
Type: clinical outcome

DCR is generally calculated as:
DCR = complete response (CR) + partial response (PR) + stable disease (SD)
Scientific Papers found: Click to Expand⟱
7000- Fuc,    Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial
- Trial, CRC, NA
DCR↑, results indicate that LMF combined with chemotarget agents significantly improved the DCR.
OS∅, OS, PFS, ORR, AEs, and QOL did not significantly differ between the two groups
PFS∅,
ORR∅,
AEs∅,
QoL∅,

7004- Fuc,    Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review
- Review, Var, NA
OS↑, Two studies revealed a significantly longer survival time and chemotherapy treatment periods with fucoidan use.
DCR↑, Positive but insignificant effects of disease control rate, inflammatory markers, nutrition status, fatigue, and financial difficulty were shown in those using fucoidan.
Inflam↓,
fatigue↓,

7061- GamB,    An open-labeled, randomized, multicentered, phase IIa study for advanced cancer treatment by gambogic acid injection (THS)
- Trial, Var, NA
ORR↑, Observed an objective remission rate (ORR) of 14.29% and an overall disease control rate (DCR) of 76.2% in arm A compare to observed an ORR of 0.00% and a DCR of 61.5% in arm B.
DCR↑,
*toxicity↓, The preliminary results of the exploratory study indicated favorable safety profiles at 45mg/m2 in this phase IIa clinical study.

7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, itraconazole group received six chemotherapy cycles and 400 mg oral itraconazole for five days per cycle.
DCR↑, The objective response rate was 80% in the itraconazole group compared with 47% in the placebo group (p = 0.015), while the disease control rate was 100% versus 80%, respectively (p = 0.023).
PFS↑, Progression-free survival was significantly improved in the itraconazole group, with 70% of patients remaining progression-free compared with 26.7% in the placebo group
CA125↓, itraconazole group produced significant declines in the serum levels of CA-125 (p = 0.005) and p-glycoprotein (p = 0.042) with significant elevation in VEGFR-2 (p = 0.006) as compared to the control group.
P-gp/ABCB1↓,
VEGFR2/KDR/Flk1↑,
toxicity↓, Itraconazole was safe and its use was associated with a significant improvement in the quality of life (QOL).
QoL↑,
toxicity↝, no significant variations observed between the two study groups in the terms of reported adverse effect of the treatment including hematological toxicity such as anemia, neutropenia, thrombocytopenia, and non-hematological toxicity such as nausea, di

8126- LF,    Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy
- NA, NSCLC, NA
Dose↝, Patients (n = 100) were randomly assigned to receive either oral TLF (1.5 g in 15 mL phosphate-based buffer) or placebo (15 mL phosphate-based buffer) twice per day in addition to supportive care.
OS↑, TLF was associated with improvement in OS in the ITT patient population, meeting the protocol-specified level of significance of a one-tailed P = .05.
PFS↑, Supportive trends were also observed for PFS and DCR.
DCR↑,
other↝, TLF demonstrated an apparent improvement in OS in patients with stages IIIB to IV NSCLC for whom one or two prior lines of systemic anticancer therapy had failed and was well tolerated.


Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

AEs∅, 1,   DCR↑, 5,   ORR↑, 1,   ORR∅, 1,   PFS↑, 2,   PFS∅, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

CA125↓, 1,  

Functional Outcomes(tgid=23) ⓘ

fatigue↓, 1,   OS↑, 2,   OS∅, 1,   QoL↑, 1,   QoL∅, 1,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 19

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: DCR, Disease control rate
2 Fucoidan
1 Gambogic Acid
1 itraconazole
1 Lactoferrin/Talactoferrin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1558  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page